SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Henry Niman who wrote (26851)12/11/1998 12:50:00 PM
From: Mudcat  Read Replies (1) | Respond to of 32384
 
<Today's WSJ has an extensive article on the 55% reduction in breast cancer among patients taking LLY's Evista (Raloxifene)>

Is this result based only on using Evista or is it due to a mixture of Evista with with one of Lgnd's products? If it is solely based on Evista, then could you explain how Lgnd fits with Lilly concerning breast cancer and osteo? How does Lgnd make money from this?